
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


West Pharmaceutical Services Inc (WST)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: WST (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $316.36
1 Year Target Price $316.36
10 | Strong Buy |
2 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.51% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 17.70B USD | Price to earnings Ratio 36.91 | 1Y Target Price 316.36 |
Price to earnings Ratio 36.91 | 1Y Target Price 316.36 | ||
Volume (30-day avg) 13 | Beta 1.05 | 52 Weeks Range 187.09 - 351.24 | Updated Date 08/15/2025 |
52 Weeks Range 187.09 - 351.24 | Updated Date 08/15/2025 | ||
Dividends yield (FY) 0.34% | Basic EPS (TTM) 6.67 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-23 | When Before Market | Estimate 1.51 | Actual 1.84 |
Profitability
Profit Margin 16.48% | Operating Margin (TTM) 20.87% |
Management Effectiveness
Return on Assets (TTM) 10.53% | Return on Equity (TTM) 17.72% |
Valuation
Trailing PE 36.91 | Forward PE 38.46 | Enterprise Value 17497183415 | Price to Sales(TTM) 5.98 |
Enterprise Value 17497183415 | Price to Sales(TTM) 5.98 | ||
Enterprise Value to Revenue 5.91 | Enterprise Value to EBITDA 23.03 | Shares Outstanding 71907296 | Shares Floating 71388873 |
Shares Outstanding 71907296 | Shares Floating 71388873 | ||
Percent Insiders 0.61 | Percent Institutions 97.94 |
Upturn AI SWOT
West Pharmaceutical Services Inc

Company Overview
History and Background
Founded in 1923, West Pharmaceutical Services has evolved from a small manufacturer of rubber closures for medicinal products to a global leader in innovative solutions for injectable drug delivery. Key milestones include the development of new closure technologies and expansion into device manufacturing and contract manufacturing services.
Core Business Areas
- Proprietary Products: Develops, manufactures, and sells stoppers, plungers, seals, and other components for injectable drug packaging and delivery systems.
- Contract-Manufactured Products: Provides contract manufacturing services for medical devices, including wearable injectors and auto-injectors.
Leadership and Structure
The leadership team is headed by the CEO, with a structure encompassing various functional departments such as operations, R&D, sales, and finance. Board of Directors provides oversight.
Top Products and Market Share
Key Offerings
- Elastomeric Closures: Provides various elastomeric closures that ensure drug integrity and purity. West is a market leader in this space, competing with Datwyler. Estimated market share is approximately 20-25% of the global elastomeric closure market for injectable drugs. Revenue is approximately 1.5 Billion. Competitors: Datwyler Holding Inc. (DWTN.SW), AptarGroup, Inc (ATR).
- Drug Delivery Devices: Designs and manufactures prefilled syringes, auto-injectors, and wearable injectors. Competing with companies like BD and Novo Nordisk in specific device markets. High-growth business driven by the increasing demand for self-administration of medications. Revenue is approximately 0.5 Billion. Competitors: Becton, Dickinson and Company (BDX), Novo Nordisk (NVO).
Market Dynamics
Industry Overview
The pharmaceutical packaging and drug delivery market is experiencing growth driven by factors such as the increasing demand for injectable drugs, biologics, and personalized medicine, as well as technological advancements in drug delivery systems.
Positioning
West Pharmaceutical Services Inc. is a leading player in the market due to its long-standing expertise, strong customer relationships, and innovative product offerings. Its competitive advantage lies in its ability to provide comprehensive solutions for drug packaging and delivery.
Total Addressable Market (TAM)
The total addressable market for pharmaceutical packaging and drug delivery is estimated to be over $100 billion. West is well-positioned to capture a significant share of this market through its established presence and innovative products.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Extensive product portfolio
- Long-standing customer relationships
- Innovative technology
- Global presence
Weaknesses
- Dependence on the pharmaceutical industry
- Exposure to raw material price fluctuations
- Competition from larger players
- High capital expenditures
Opportunities
- Growing demand for biologics and injectable drugs
- Expansion into emerging markets
- Development of new drug delivery technologies
- Increasing adoption of self-administration of medications
- Strategic acquisitions
Threats
- Intense competition
- Regulatory changes
- Product liability claims
- Economic downturns
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- DWTN.SW
- ATR
- BDX
Competitive Landscape
West competes on product quality, innovation, and customer service. It has a strong advantage in its established customer relationships and specialized expertise, but faces competition from larger, more diversified companies.
Major Acquisitions
Medimop Medical Projects Ltd.
- Year: 2017
- Acquisition Price (USD millions): 147.5
- Strategic Rationale: Expanded Westu2019s self-injection and drug delivery capabilities.
Growth Trajectory and Initiatives
Historical Growth: West Pharmaceutical Services Inc. has experienced consistent revenue growth over the past decade, driven by increasing demand for its products and services.
Future Projections: Analysts project continued revenue growth for West Pharmaceutical Services Inc. in the coming years, driven by factors such as the aging population, the increasing prevalence of chronic diseases, and the development of new injectable drugs.
Recent Initiatives: Recent strategic initiatives include expanding manufacturing capacity, investing in R&D, and pursuing acquisitions to strengthen its market position.
Summary
West Pharmaceutical Services is a well-established company with a strong market position in the pharmaceutical packaging and drug delivery industry. Its focus on innovation and customer relationships is working well, contributing to consistent revenue growth. However, competition remains intense, and the company needs to carefully manage its exposure to raw material price fluctuations and potential regulatory changes. The company should focus on further innovation in injectable drug delivery to stay ahead.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q), Investor Presentations, Analyst Reports, Market Research Reports
- West Pharmaceutical Services Website
Disclaimers:
The data and analysis provided are based on available information and are subject to change. This is not financial advice. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About West Pharmaceutical Services Inc
Exchange NYSE | Headquaters Exton, PA, United States | ||
IPO Launch date 1978-01-13 | Non-Independent Chair of the Board, President & CEO Mr. Eric M. Green | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 10600 | Website https://www.westpharma.com |
Full time employees 10600 | Website https://www.westpharma.com |
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.